Skip to content

Cardiac Rehabilitation for the Treatment of Refractory Angina

Cardiac Rehabilitation for the Treatment of Refractory Angina

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00411359
Enrollment
42
Registered
2006-12-14
Start date
2006-12-31
Completion date
2010-04-30
Last updated
2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris, Coronary Disease

Keywords

Refractory angina, Cardiac rehabilitation, Symptomology, Physical ability, Exercise, Psychology, Quality of life, Risk factors

Brief summary

The purpose of this study is to determine whether cardiac rehabilitation is a successful treatment for refractory angina, in relation to improvements in cardiovascular risk factors, physical ability, symptomology, quality of life and psychological morbidity.

Detailed description

The majority of patients presenting with angina pectoris resulting from coronary artery disease (CHD) are successfully treated with interventions including coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA) and medical management. However, a growing number of patients experience persistent angina in spite of intervention and optimal medical treatment. Such patients are referred to as suffering from 'refractory angina'. Currently, cardiac rehabilitation centres are reluctant to accept patients with ongoing angina or complicated cardiovascular history, in spite of the duration or stability of the symptoms. Indeed, angina and heart failure are often used to exclude patients from cardiac rehabilitation. However, in the recent updated American Heart Association (AHA) recommendations for exercise and training, cardiac rehabilitation and supervised exercise training is recommended for patients with ongoing angina, previous history of CABG, MI, PTCA and patients with existing cardiomyopathy in order to promote a reduction in myocardial ischaemia at rest and during sub-maximal exercise, while reducing the risk for the progression of CHD. Nevertheless, studies exploring the physiological and psychological impact of routinely available CR as a stand-alone intervention among refractory angina patients have not previously been undertaken. Until such studies are performed, CR practitioners will continue to refuse to accept refractory angina patients for participation in CR. Research questions: * Is an eight-week cardiac rehabilitation exercise programme an appropriate treatment option for patients with refractory angina? * Does an eight-week cardiac rehabilitation exercise programme improve the physical functioning and cardiovascular health of patients with refractory angina? * Is symptom severity and frequency reduced following an eight-week cardiac rehabilitation exercise programme in patients with refractory angina? * Does an eight-week cardiac rehabilitation exercise programme have any impact on anxiety, depression, cardiac anxiety and quality of life in patients with refractory angina? * Are any physiological or psychological effects acquired by patients with refractory angina participating in a cardiac rehabilitation exercise programme maintained at an eight-week follow-up? The study is conceived as a randomised intervention-control study of a standard, routinely available Phase III hospital-based CR program among patients with refractory angina. Patients will be randomly assigned to an eight-week CR programme based at Harefield Hospital or symptom diary monitoring control group.

Interventions

BEHAVIORALCardiac rehabilitation

Phase III cardiac rehabilitation programme

Sponsors

British Heart Foundation
CollaboratorOTHER
Royal Brompton & Harefield NHS Foundation Trust
CollaboratorOTHER
National Heart and Lung Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Clinically diagnosed with refractory angina \> 6 months * Two or more episodes of angina per week * Males and females aged 30 - 80 * Previous history of single or multiple myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or any combination of the above * Prescribed optimal medical therapy * AHA exercise and training guidelines classification B and C * Willing to give written informed consent

Exclusion criteria

* History of any other chronic illness * AHA exercise and training guidelines classification class D * Suffer any physical condition for which exercise is a contra-indication * Participation in two or more periods of planned moderate intensity exercise per week during the past 6 months * Participation in another research study within the previous 60 days * History of psychiatric illness * Unwilling to give written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Health anxietyBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Health anxiety questionnaire (HAQ)
Generalised anxiety and depressionBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Hospital Anxiety and Depression scale (HADS)

Secondary

MeasureTime frameDescription
AnthropomometryBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Weight, height, waist circumference (tape measure), hip circumference (tape measure), body mass index calculated from height and weight using the following website: http://www.nhlbisupport.com/bmi/bmi-m.htm
Fasting lipidsBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides. Measured in biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.
Social supportBaselineMeasured using the ENRICHED social support instrument (ESSI)
Angina related health beliefsBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Measured using the York angina beliefs scale.
Physical activity and exercise capacityBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Progressive shuttle walk test
Angina frequency and severityBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Subjects completed a daily symptom monitoring diary
Systolic and diastolic blood pressureBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Measured after 10 minutes sitting, using automated machine (eg. Omron machine)
Plasma glucoseBase, post intervention/monitoring, 8 weeks post intervention/monitoringMeasured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.
Urea & electrolytesBase, post intervention/monitoring, 8 weeks post intervention/monitoringMeasured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques
Liver function testsBaseline, post intervention/monitoring, 8 weeks post intervention/monitoringMeasured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.
Thyroid function testsBaseline, post intervention/monitoring, 8 weeks post intervention/monitoringMeasured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.
HbBaseline, post intervention/monitoring, 8 weeks post intervention/monitoringMeasured in the haematology departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.
HbA1C (if diabetic)Baseline, post intervention/monitoring, 8 weeks post intervention/monitoringMeasured in the haematology department of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques
Quality of lifeBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)SF-36 quality of life scale
Heart rateBase, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)Heart rate measured using automated machine (eg. Omron blood pressure machine) or manually at the radial pulse

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026